These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 16838393)

  • 1. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease.
    Leite AC; Pedro AB; Romaldini JH
    Horm Metab Res; 2011 Mar; 43(3):194-9. PubMed ID: 21283953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
    Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
    J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases.
    Inukai T; Takanashi K; Takebayashi K; Fujiwara Y; Tayama K; Takemura Y
    Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum neopterin levels in patients with Graves' disease.
    Wagner R; Hayatghebi S; Rosenkranz M; Reinwein D
    Exp Clin Endocrinol; 1993; 101(4):249-54. PubMed ID: 8307114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
    Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
    Antonelli A; Ferrari SM; Corrado A; Ferrannini E; Fallahi P
    Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcome of Graves' disease in Thai children.
    Somnuke PH; Pusuwan P; Likitmaskul S; Santiprabhob J; Sawathiparnich P
    J Med Assoc Thai; 2007 Sep; 90(9):1815-20. PubMed ID: 17957924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes.
    Crescioli C; Cosmi L; Borgogni E; Santarlasci V; Gelmini S; Sottili M; Sarchielli E; Mazzinghi B; Francalanci M; Pezzatini A; Perigli G; Vannelli GB; Annunziato F; Serio M
    J Endocrinol; 2007 Oct; 195(1):145-55. PubMed ID: 17911406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
    Molnár I; Bokk A
    Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
    Wakelkamp IM; Prummel MF; Wiersinga WM
    Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process.
    Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Romagnani P; Grosso M; Ferrannini E; Serio M
    Eur J Endocrinol; 2006 May; 154(5):651-8. PubMed ID: 16645011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cytokines levels in Graves' disease.
    Al-Humaidi MA
    Saudi Med J; 2000 Jul; 21(7):639-44. PubMed ID: 11500727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of antithyroid drugs efficacy on P wave changes in patients with Graves' disease.
    Berker D; Işik S; Canbay A; Aydin Y; Tütüncü Y; Delibaşi T; Güler S
    Anadolu Kardiyol Derg; 2009 Aug; 9(4):298-303. PubMed ID: 19666432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Rotondi M; Ferrari SM; Fallahi P; Romagnani P; Franceschini SS; Serio M; Ferrannini E
    J Clin Endocrinol Metab; 2006 Feb; 91(2):614-20. PubMed ID: 16303841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithyroid drug-induced immunomodulation in Graves' disease patients.
    Lechpammer M; Lukac J; Lechpammer S; Kusić Z
    Acta Med Croatica; 2002; 56(1):21-6. PubMed ID: 12455450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.